Submit Deal

Announced

23 Jun 2020

Harbin Pharmaceutical Group to acquire GNC Holdings for $760m.

Synopsis

Harbin Pharmaceutical Group, a Chinese partially state-owned pharmaceutical manufacturer, agreed to acquire GNC Holdings, a provider of health and nutrition-related products, including vitamins, supplements, minerals, herbs, sports nutrition, diet, and energy products, for $760m.

Principals

target

Gnc Holdings

bidder

Harbin Pharmaceutical Group Holding Co

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (12)

ken martindale

Chairman and CEO at GNC HOLDINGS

Manager

target

Deals

£ 751 M

Total Value

rachel rosenblatt

Senior Managing Director at FTI Consulting

PR Consultant

target

Deals

£ 6.30 B

Total Value

asif attarwala

Associate at Latham & Watkins

Lawyer

target

Deal

£ 612 M

Total Value

tricia tolivar

CFO at GNC HOLDINGS

Manager

target

Deal

£ 612 M

Total Value

caroline reckler

Partner at Latham & Watkins

Lawyer

target

Deals

£ 790 M

Total Value

rachel chesley

Managing Director at FTI Consulting

PR Consultant

target

Deals

£ 2.94 B

Total Value

george a. davis

Partner at Latham & Watkins

Lawyer

target

Deals

£ 1.32 B

Total Value

bradley faris

Partner at Latham & Watkins

Lawyer

target

Deals

£ 220.47 B

Total Value

andrew ambruoso

Counsel at Latham & Watkins

Lawyer

target

Deal

£ 612 M

Total Value

brett newman

Associate at Latham & Watkins

Lawyer

target

Deals

£ 8.61 B

Total Value

jeffrey mispagel

Partner at Latham & Watkins

Lawyer

target

Deal

£ 612 M

Total Value

richard a. levy

Partner at Latham & Watkins

Lawyer

target

Deal

£ 612 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy